---
title: Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis
nct_id: NCT01626911
overall_status: UNKNOWN
phase: NA
sponsor: Nanjing University School of Medicine
study_type: INTERVENTIONAL
primary_condition: Acute Pancreatitis
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01626911.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01626911"
ct_last_update_post_date: 2013-12-09
last_seen_at: "2026-05-12T07:21:15.013Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis

**NCT ID:** [NCT01626911](https://clinicaltrials.gov/study/NCT01626911)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** Nanjing University School of Medicine
- **Conditions:** Acute Pancreatitis
- **Start Date:** 2011-09
- **CT.gov Last Update:** 2013-12-09

## Brief Summary

Our animal studies found that continuous regional arterial infusion (CRAI in the celiac trunk) of low molecular weight heparin (LMWH) could alleviate inflammation, improve global hemodynamics and restore organ function in a porcine model of severe acute pancreatitis (SAP,unpublished).

In this study, the investigators aim to evaluate the effects of CRAI of LMWH in the treatment of SAP patients. The investigators suppose CRAI could help improve the outcomes of these patients.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Symptoms and signs of severe acute pancreatitis according to Atlanta criteria
* Within 3 days from the onset of the disease
* Available for interventional treatment(not sensible to radiocontrast agent)

Exclusion Criteria:

* Pregnant pancreatitis
* Receiving surgery or aspiration before;need of early surgery
* Patients with coagulation disorders
```

## Arms

- **CRAI** (EXPERIMENTAL) — CRAI of LMWH in the celiac trunk
- **Conservative treatment** (OTHER) — Conservative treatment without CRAI, control group

## Interventions

- **Continuous regional arterial infusion of low molecular weight heparin in celiac trunk** (PROCEDURE) — Put a catheter to the celiac trunk through interventional technique. The approach to celiac trunk was via a femoral artery approach.The tip of the arterial catheter (4F) was placed in celiac trunk which could perfuse the pancreas.After that, continuous infusion of low molecular weight heparin through the catheter will be applied during the first 5 days after placement.
- **General treatment** (OTHER) — Include fluid resuscitation, percutaneous drainage if needed, antibiotics,organ support, etc.

## Primary Outcomes

- **coagulation related complications** _(time frame: 14 days after the placement of celiac trunk catheter)_ — bleeding for the most

coagulative parameters
- **Pancreatic infection** _(time frame: 28 days)_

## Secondary Outcomes

- **pancreatic necrosis** _(time frame: 28 days)_
- **ICU duration** _(time frame: Participants will be followed until the date of discharge from the ICU,assessed up to 6 weeks. Patients who die during hospitalization are excluded from this measurement.)_
- **Hospital duration** _(time frame: Participants will be followed until the date of discharge from the hospital,assessed up to 3 months. Patients who die during hospitalization are excluded from this measurement.)_
- **Mortality** _(time frame: Participants will be followed until the date of discharge or the date of death from any cause, whichever came first, assessed up to 3 months)_

## Locations (1)

- Department of SICU, Research Institute of General Surgery Jinling Hospital, Nanjing, Jiangsu, China, Nanjing, Jiangsu, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.department of sicu, research institute of general surgery jinling hospital, nanjing, jiangsu, china|nanjing|jiangsu|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01626911.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01626911*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*